SABCS Expert Commentary | Professor Wang Xin: ctDNA Clearance Predicts pCR in HER2-Positive Breast Cancer and Supports Precision De-escalation Strategies

SABCS Expert Commentary | Professor Wang Xin: ctDNA Clearance Predicts pCR in HER2-Positive Breast Cancer and Supports Precision De-escalation Strategies

2026.01.13
De-escalation therapy has become an important trend in the management of HER2-positive early breast cancer, yet accurately identifying patients who can safely omit chemotherapy remains a major challenge. At the 2025 San Antonio Breast Cancer Symposium (SABCS), the PHERGuide substudy innovatively incorporated circulating tumor DNA (ctDNA) monitoring into the neoadjuvant treatment framework. The study demonstrated that ctDNA clearance is strongly associated with pathological complete response (pCR), while baseline ctDNA positivity predicts poorer outcomes.
SABCS Expert Commentary | Professor Jin Feng: Precision Immunotherapy Adds New Evidence in Early Triple-Negative Breast Cancer—Gene Expression–Based Subtyping Predicts Response to Neoadjuvant Immunochemotherapy

SABCS Expert Commentary | Professor Jin Feng: Precision Immunotherapy Adds New Evidence in Early Triple-Negative Breast Cancer—Gene Expression–Based Subtyping Predicts Response to Neoadjuvant Immunochemotherapy

2026.01.04
At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study entitled “Gene Expression–based Subtyping of Early Triple-Negative Breast Cancer for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial” (Abstract No. RF3-02) was presented. This study provides an in-depth analysis of the heterogeneity of benefit from immunotherapy in early-stage triple-negative breast cancer (TNBC), highlighting the predictive value of tumor-infiltrating lymphocytes (TILs) and TNBC molecular subtypes. Oncology Frontier invited Professor Jin Feng and his colleagues Professor Yu Xinmiao and Professor Zheng Ang from the First Hospital of China Medical University to introduce and comment on the study in detail, offering important evidence and clinical insights for precision immunotherapy in TNBC.